Advertisement

Topics

Companies Related to "A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib" [Most Relevant Company Matches] RSS

22:00 EST 21st February 2019 | BioPortfolio

Here are the most relevant search results for "A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib" found in our extensive corporate database of over 50,000 company records.

Showing "Study Cancer Patients Evaluate Bioequivalence Alternative Formulations Lapatinib" Companies 1–25 of 6,600+

Relevant

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.


Atlantic Life Sciences, Inc

Atlantic Life Sciences, Inc., Provider of Tailored Clinical Services ALS Inc. is located in Montreal.It is one of the world-class CRO where the Experience, the Expertise and the Strategic Project Management create a value addition for the study success. Since its inception, Atlantic Life Sciences Inc. accomplishes clinical studies with a top quality. Each study is unique. Since 2003, ALS Inc. cond...

Genta Incorporated

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead com...


BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

The German Breast Group and Celgene Corporation

GBG is a large independent academic network of over 500 study centers in Germany with the world- wide largest experience in conducting neoadjuvant breast cancer trials. Since 1998, with joined forces from AGO-B, over 10.000 patients participated in the neoadjuvant “Gepardo” trial series. GBG has recruited at totality of over 35.000 patients to tr...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Cancer Consultants.Inc

Cancer Consultants was founded in 1998 by experts in the field of oncology in order to facilitate information transfer on the management of cancer to patients and health care providers. Because cancer is chronic, life threatening, associated with rapid technological advancements, and patients have time to evaluate their treatment options before making a decision, Cancer Consultants, Inc. recognize...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

PHAROS GmbH

PHAROS GmbH is a Contract Research Organisation for Early Clinical Research and various related services. All of our services are custom designed, thus these pages are only a guide to the types of services we are able to offer.Our main services are:Clinical Trial Services• Phase I Study Services• Bioequivalence Study Services• Clinical Trial Elements and ProceduresQuality Management Services...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Navigating Cancer

Navigating Cancer is dedicated to empowering cancer patients to navigate their best care. Navigating Cancer, www.navigatingcancer.com, is a free web application that offers personalized tools and authoritative cancer resources to help patients take control of their health and partner more closely with their physicians, support network and other like patien...

Naryx Pharma, Inc.

Naryx Pharma is a specialty pharmaceutical company that is developing promising propriety medication formulations for the FDA approval process. Naryx Pharma is focused on development of its product candidates of inhaled, nebulized, intranasal drug formulations. The approvals will enable Naryx Pharma to market and distribute formulations that will fulfill an unmet medical need for the treatment of ...

Tapestry Pharmaceuticals

Tapestry Pharmaceuticals, Inc. is a company focused on developing proprietary therapies for the treatment of cancer. We are also actively engaged in evaluating new therapeutic agents and related technologies for in-licensing. Tapestry's technical expertise is our ability to identify, chemically alter and produce novel therapeutic compounds derived from natural product sources. Tapestry has devel...

Intarcia Therapeutics, Inc

Intarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. Our highly experienced team uses its expertise in clinical medicine, pharmaceutical development and regulatory affairs to identify and develop new uses or alternative formulat...

HST Global, Inc.

HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In thi...

MyHealthHerbals.com

MyHealthHerbals.com was launched by Andrew Gaeddert, nationally known herbalist, author, and founder of Health Concerns (www.healthconcerns.com), to bring the healing benefits of herbal and natural formulations to the consumer market. After 26 years providing herbal formulations for the alternative medicine profession, Gaeddert wanted to provide the same n...

Azelon Pharmaceuticals, Inc.

Azelon Pharmaceuticals is focused on the development of novel formulations for the treatment of osteoporosis. Its lead program, ZT-034, a nasal spray formulation of teriparatide (PTH1-34), offers a convenient alternative for patients at high risk of fracture. Led by an experienced team of biopharmaceutical executives and funded by leading venture cap...

Genetronics Biomedical

Genetronics' most advanced effort involves treating those with head and neck cancer, a particularly devastating cancer that can severely limit the ability of these patients to see, taste, hear, talk, breathe, or swallow. Genetronics received approval from the U.S. Food and Drug Administration and initiated Phase II multi-center clinical trials at nine sites in the U.S. The trials test the effectiv...

The North Shore-LIJ Cancer Institute

The North Shore-LIJ Cancer Institute is one of the largest cancer providers in the New York metropolitan area. With 200 physicians, the Cancer Institute diagnoses and/or treats more than 16,000 cancer patients each year. Its multidisciplinary teams develop individualized treatment plans that address patients’ physical and emotional needs through 12 di...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

Nagourney Cancer Institute

The Nagourney Cancer Institute is a clinical research center that has pioneered the study of human tumor tissue for individualized cancer patient drug selection and has facilitated cancer drug discovery.

Beckstrand Cancer Foundation

Beckstrand Cancer Foundation is a 501(c)(3) organization founded in 1974 by Dr. Grant Beckstrand and a group of doctors specializing in the treatment and care of cancer patients. The Foundation’s goal has been to improve and enhance the quality of life for cancer patients and their families, a mission achieved through unique programs which provide fin...


More From BioPortfolio on "A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks